Conditions: Metabolic Syndrome Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 125
Healthy volunteers: no

Brief summary:
258 patients who have been treated for at least 3 months with oral olanzapine, risperidone or quetiapine in the treatment of schizophrenia and currently presenting with metabolic syndrome, will be randomized to: i) aripiprazole for 16 weeks, with flexible dosing within a range of 10 to 30 mg once daily (QD); or ii) continue for 16 weeks on the same atypical antipsychotic treatment prior to the study enrollment.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Aripiprazole intervention 2: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Intervention descriptions: intervention 1: Tablets, Oral, 5 to 30 mg, once daily, 16 weeks intervention 2: Tablets, Oral, According to summary of product characteristics (SmPC)

Protocol document: